. Usually the AHN is an aggressive neoplasm that can be challenging to diagnose either because the mast cell infiltrate can be subtle and difficult to identify or because the mast cell infiltrate can be prominent, thus obscuring the underlying AHN. Frequently the AHN is represented by a myeloid neoplasm, whereas the observation of an association between SM and lymphoproliferative diseases is uncommon. In particular, chronic lymphocytic leukemia (CLL) in the context of SM-AHN has been rarely reported [2, 3, 4, 5, 6] (Table 1) . Here, we describe a new case of SM with associated CLL, in which the cytological features of the two neoplasias were evident in bone marrow aspirate; moreover, in this case molecular analysis specific for SM was performed. , whereas fluorescent in situ hybridization, performed with probes specific for chromosomal aberrations associated with CLL, revealed the presence of del(13) (q14) and no alterations at the 17p13, 11q22, and 12q13 loci. IGVH was not mutated. Molecular analysis revealed the KIT D816V mutation, whereas SRSF2, ASXL1, and JAK2 V617F were not altered. Based upon these findings, the patient was diagnosed with SM (the major criterion and 3 minor criteria) with associated CLL (Rai 0, Binet A stage). Since neither of the two diseases showed signs of activity it was decided to choose a "watch and wait" strategy, and 1 year after the diagnosis the SM-AHN remains stable (lymphocyte absolute count, 92x10 9 cells/L; tryptase level, 67 ng/mL) and the patient is doing well. Reportedly, SM-AHN has a poor prognosis with a median survival of less than 2-4 years [7] . Given the low frequency of CLL in the context of SM-AHN, it is very difficult to draw general prognostic considerations for this entity, but recently it was published that advanced SM patients bearing SRSF2 and/or ASXL1 mutations have a poor prognosis [8, 9] . Note that among the SM patients reported in those two studies there was not a case associated with CLL. In conclusion, we suggest that the stable course of SM-AHN may derive from the concurrence of the positive prognostic factors that characterize the two diseases in our patient. 
